NuVasive Reports 2.4% Net Sales Growth in Q2 2023

NuVasive Inc., a leader in spine technology innovation, has announced financial results for the quarter ended June 30, 2023.
 
NuVasive reported second quarter 2023 total net sales of $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basis, compared to $310.5 million in the prior year period. Second quarter 2023 total net sales were primarily driven by further adoption of new products and higher procedural volumes in the U.S.
 
“I’d like to congratulate our team on another solid quarter,” said Chris Barry, chief executive officer of NuVasive. “Our results reflect the strength of our differentiated product portfolios and continued commercial execution.”

Full-year 2023 Net Sales Guidance

The company continues to expect 2023 net sales growth of 6%-8% on an as reported and constant currency basis, compared to full year 2022, based on foreign currency rates as of July 31, 2023.
 
“Looking ahead, we remain excited and committed to combining with Globus Medical. And in doing so, drive value creation for our shareholders as we help change more patient lives around the globe,” Barry added.